Steven Leonard Chapman Sells 5,583 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 5,583 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $118.91, for a total value of $663,874.53. Following the sale, the chief executive officer now directly owns 200,710 shares in the company, valued at approximately $23,866,426.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $102.77, for a total value of $419,712.68.
• On Monday, July 22nd, Steven Leonard Chapman sold 2,638 shares of Natera stock. The shares were sold at an average price of $105.16, for a total transaction of $277,412.08.
• On Monday, July 15th, Steven Leonard Chapman sold 5,496 shares of Natera stock. The stock was sold at an average price of $111.66, for a total transaction of $613,683.36.
• On Monday, July 1st, Steven Leonard Chapman sold 37,500 shares of Natera stock. The stock was sold at an average price of $108.10, for a total transaction of $4,053,750.00.
• On Monday, June 17th, Steven Leonard Chapman sold 6,105 shares of Natera stock. The shares were sold at an average price of $111.61, for a total value of $681,379.05.

Natera Stock Down 4.3 %

NTRA opened at $118.45 on Wednesday. The stock’s fifty day simple moving average is $109.34 and its 200 day simple moving average is $98.03. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $124.72. The stock has a market cap of $14.55 billion, a PE ratio of -37.96 and a beta of 1.48. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The company’s revenue was up 58.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.97) earnings per share. As a group, research analysts expect that Natera, Inc. will post -2.43 earnings per share for the current year.

Institutional Investors Weigh In On Natera

Several hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC grew its position in shares of Natera by 1,073.1% in the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after purchasing an additional 60,127 shares during the last quarter. Thematics Asset Management increased its position in Natera by 3.1% during the 4th quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock worth $5,652,000 after buying an additional 2,738 shares during the period. Crestline Management LP increased its position in Natera by 16.0% during the 4th quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock worth $4,076,000 after buying an additional 8,997 shares during the period. Hamilton Lane Advisors LLC acquired a new stake in shares of Natera during the fourth quarter worth $616,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Natera by 15.1% in the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after acquiring an additional 9,781 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Stephens reiterated an “overweight” rating and set a $125.00 price objective on shares of Natera in a report on Friday, August 9th. Canaccord Genuity Group boosted their price objective on shares of Natera from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Morgan Stanley raised their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Jefferies Financial Group began coverage on shares of Natera in a research report on Monday, June 3rd. They set a “buy” rating and a $142.00 price target on the stock. Finally, Piper Sandler raised their price objective on Natera from $120.00 to $150.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $119.07.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.